Trial · NCT07877272
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
NCT07877272, Recruiting, University Hospital Muenster
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD. Trials, record NCT07877272. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877272
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
- NCT number
- NCT07877272
- Status
- Recruiting
- Enrollment
- 500 participants, estimated
- Lead sponsor
- University Hospital Muenster
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Liver Fibrosis, Portal Hypertension
- Interventions
- Non-invasive MASLD and portal hypertension assessment, Single-session endohepatology assessment
- First posted
- 2026-10-16
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants with a change in treatment indication after endohepatology | At baseline endohepatology assessment, approximately 4 to 8 weeks after screening | Any change in the indication for MASH-directed pharmacotherapy and/or non-selective beta-blocker therapy compared with the prospectively documented non-invasive indication. |
| Secondary | Prevalence of histologically significant fibrosis | At baseline endohepatology assessment | NASH-CRN fibrosis stage F2 or higher. |
| Secondary | Prevalence of EUS-PPG of 10 mmHg or higher | At baseline endohepatology assessment | Clinically significant portal hypertension by EUS-PPG threshold. |
| Secondary | Procedure-associated serious adverse events | Up to 30 days after each endohepatology procedure | Serious adverse events related to endoscopy, EUS, pressure measurement or biopsy. |
| Secondary | Hepatic decompensation | From enrollment through month 24 | Occurence of hepatic decompensation defined as hepatic encephalopathy and/or ascites and/or variceal bleeding |
| Secondary | Hepatocellular carcinoma | From enrollment through month 24 | Development of hepatocellular carcinoma |
| Secondary | Major adverse cardiovascular events | From enrollment through month 24 | Occurence of MACE-Event (cardiovascular death and/or non-deadly myocardial infarction and/or stroke) |
| Secondary | Liver transplantation | From enrollment through month 24 | Liver transplantation within the study period |
| Secondary | Mortality | From enrollment through month 24 | Death within the study period |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers23
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877272
GET https://conductscience.org/api/trials/v1/NCT07877272/papers?page=2